

MEDIA ANNOUNCEMENT

**AMGEN ANNOUNCES CONTINUATION OF #PROTECTURLIFE
HEART AND BONE HEALTH SCREENING PROGRAM
IN FIVE MAJOR EUROPEAN CITIES**

**Unique events provide free health screening for active aging residents
who may be at risk of cardiovascular disease and osteoporosis**

**Innovative 'predict and prevent' campaign designed to support
cities and policy makers with their efforts to develop sustainable
healthcare systems that benefit their residents**

ROTKREUZ, Switzerland, 30 August, 2019, AMGEN (Europe) GmbH today announced that starting this weekend, the #ProtectUrLife campaign will be continued across five major European cities to improve the prevention, evaluation and care of cardiovascular disease (CVD) and osteoporosis – two serious medical conditions that continue to be underdiagnosed and undermanaged. Initiated by Amgen in 2018, #ProtectUrLife is an innovative heart and bone screening and education program designed to empower the aging population to act on vital knowledge to help prevent life-altering events such as heart attack, stroke and bone fracture.

The first of the Europe-wide events will take place in the Public Event Village held in front of the Hôtel de Ville in Paris this weekend, Aug. 31 and Sept. 1. The Public Event is being organized by the European Society of Cardiology (ESC), the French Society of Cardiology and the City of Paris to raise awareness of CVD and runs in parallel with ESC Congress 2019 together with the World Congress of Cardiology, which is being hosted in the city. #ProtectUrLife public events are also planned to take place later in the year in Munich and Malaga, Nov. 15-16, in Lucerne, Nov. 16-17 and in Rimini, Nov. 22-24. Residents are invited to evaluate their heart and bone health with free cholesterol and bone density screenings

"Our #ProtectUrLife screening and education program aims to improve the prevention, evaluation and care of heart and bone health, which continue to be underdiagnosed and undermanaged," said Isma Benattia, M.D., vice president of Medical for the European Region at Amgen. "Moving on from the traditional 'break and fix' approach, the program uses a 'predict and prevent' model, providing education on risk reduction and empowering the public to take action and help prevent life-altering events such as heart attack, stroke and bone fracture."

The non-invasive screenings will predict individualized risk of heart attack and stroke, based on cholesterol levels, as well as risk of osteoporosis based on bone density assessments. With the help of health consultants at the events, participants are also provided with education and tools to help them understand what precautions they can take to reduce their risks. During the 2018 events, more than 2,250 European residents over 50 years of age were screened. The results of the cardiovascular and bone health screenings showed that, over a 10-year period, 10% of the participants were at very high or high risk for fatal heart disease, 74% were at moderate risk for fatal heart disease, and over 22% were at high risk of a major bone fracture.

#PROTECT URLIFE

“We are very pleased to continue our partnership with Amgen to host five new #ProtectUrLife events in 2019,” said Dr. Ursula Mühle, EIT Health Education Director. “At EIT Health, we aim to improve the health and well-being of European residents, and the #ProtectUrLife initiative is a very good example of this. The events leverage innovative medical tools to highlight the importance of healthy aging and support the efforts of cities and policy makers to develop sustainable healthcare systems that benefit their residents.”

CVD is the leading cause of death in Europe, accounting for nearly 45% of all deaths and has an estimated annual cost to the European economy of €210 billion.¹ Management of CVD requires taking action on modifiable risk factors, including excess low-density lipoprotein cholesterol (LDL-C). Lowering LDL-C is a key modifiable risk factor in reducing the risk of CV events and is particularly important for those who may have already experienced a CV event such as a heart attack.

Over the age of 70 years, it is estimated that nearly a third of women and a fifth of men will suffer a bone fracture due to osteoporosis, a disease of the skeleton characterized by low bone mass and a deterioration of the bone tissue.² A real-world study in Europe has further shown that 55% of women over the age of 70 years are at risk of fragility fractures and 75% of these women are not being treated for osteoporosis.³ Incidents and previous fractures are estimated to cost the European economy €37 billion per year.⁴

About #ProtectUrLife

The #ProtectUrLife campaign aims to improve heart and bone health through prevention, evaluation and care of cardiovascular disease and osteoporosis. Using the ‘predict and prevent’ model, #ProtectUrLife events offer free screening and individualized risk assessments for aging residents to help predict who is at risk for heart attack, stroke and bone fracture. Education for improving heart and bone health is offered, empowering the public to act on knowledge and avoid life-altering events. The #ProtectUrLife initiative is also designed to empower cities and policy makers to develop sustainable healthcare systems that benefit their residents.

Launched in 2018, the campaign is led by Amgen and has been developed in partnership with EIT Health, the Technical University of Munich, the University of Barcelona and BePatient, and is endorsed by the International Osteoporosis Foundation and the World Heart Federation. The campaign unites a European consortium composed of experts, start-ups, professional societies, patient associations, healthcare professionals, hospitals and cities.

For more information about the campaign visit www.protecturlife.eu and follow us on www.twitter.com/protecturlife and www.facebook.com/ProtectUrLife19/.

About Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be the world’s largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen

#PROTECT URLIFE

About EIT Health

EIT Health is a network of best-in-class health innovators backed by the EU. We collaborate across borders to deliver new solutions that can enable European citizens to live longer, healthier lives. As Europeans tackle the challenge of increasing chronic diseases and multi-morbidity, and seek to realise the opportunities that technology offers to move beyond conventional approaches to treatment, prevention and healthy lifestyles, we need thought leaders, innovators and efficient ways to bring innovative healthcare solutions to market.

EIT Health addresses these needs. We connect all relevant healthcare players across European borders – making sure to include all sides of the “knowledge triangle”, so that innovation can happen at the intersection of research, education and business for the benefit of citizens.

EIT Health: Together for healthy lives in Europe.

For more information: www.eithealth.eu

About IOF

The International Osteoporosis Foundation (IOF) is a registered not-for-profit, non-governmental foundation that functions as a global alliance of patient societies, research organizations, healthcare professionals, and international companies working to promote bone, muscle, and joint health. IOF aims to empower people to take action to prevent, diagnose, and treat bone disorders, and to campaign for policy change to make bone health a healthcare priority.

For more information: www.iofbonehealth.org

About the World Heart Federation

The World Heart Federation is dedicated to leading the global fight against cardiovascular disease (CVD), including heart disease and stroke. We are the only global advocacy and leadership organization bringing together the entire CVD community to drive the CVD agenda and help people live longer, better, more heart-healthy lives. We and our Members - more than 200 organizations, scientific societies, foundations and patient associations in over 100 countries - believe in a world where heart health for everyone is a fundamental human right and a crucial element of global health justice. Because every heartbeat matters.

For more information: www.world-heart-federation.org/

About the Technical University of Munich

The Technical University of Munich (TUM) is one of Europe’s top universities. It is committed to excellence in research and teaching, interdisciplinary education, and the active promotion of promising young scientists. Part of TUM’s mission statement is to support and enable an innovative society, foster an open, culturally diverse mindset, and be engaged in dialogue with society and the general public.

For more information: www.tum.de

About The University of Barcelona

The University of Barcelona is one of Europe’s leading universities, often benchmarked for research activity in terms of the number of programs and excellence achieved. The university works externally to provide services in the selection of personalized lifelong learning resources, tools to facilitate the transfer of knowledge generated by research, solutions to provide market value, and professional integration and orientation.

For more information: www.ub.edu

#PROTECT URLIFE

About BePatient

BePatient is a digital health platform aiming to provide eHealth solutions to reinvent the patient journey and improve continuity of care. The company brings together health database management specialists, developers, health professionals, and experts in digital marketing. BePatient has multiple product lines that aim to promote disease awareness and prevention, support hospitalization, educate and engage patients in the management of chronic diseases, and provide an active collaboration between patients and research.

For more information: www.bepatient.com

Forward-Looking Statements

This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products.

#PROTECT URLIFE

Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to acquire other companies or products and to integrate the operations of companies we have acquired may not be successful. A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.

###

The media are also invited to participate in these events, further helping to educate the public by describing their experiences and how people may benefit from these opportunities.

Media contact:

AMGEN (Europe) GmbH
EuropeHubPressTeam@amgen.com

Project contact:

Contact@protecturlife.eu

References

1. European Health Network. European Cardiovascular Disease Statistics 2017. Available from: <http://www.ehnheart.org/cvd-statistics/cvd-statistics-2017.html>. Accessed: July 2019.
 2. Kanis, J.A., Johnell, O., Oden, A. et al. Long-term risk of osteoporotic fracture in Malmö. *Osteoporos Int.* 2000; 11: 669–74.
 3. E. V. McCloskey et al. Osteoporosis diagnosis and treatment of women aged >70 years in primary care: results from a large European cross-sectional study. Abstract P997, available from: <http://2019.wco-iof-esceo.org/sites/wco19/pdf/WCO19-AbstractBook.pdf>. Accessed: July 2019.
 4. Svedborn, A., Hemlund, E, Ivergard, M. et al. Osteoporosis in the European Union: a compendium of country-specific reports. *Arch Osteoporos* 2013; 8: 137.
-